All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the Society of Hematologic Oncology (SOHO) 2022 Annual Meeting, the Lymphoma Hub spoke with Professor Catherine Thieblemont from the Hôpital Saint-Louis, Paris, France. We asked, How can we improve care for elderly patients with aggressive lymphomas?
How can we improve care for elderly patients with aggressive lymphomas?
Thieblemont explains our improved ability to predict treatment responses according to baseline risk and discusses how recent phase II trials have contributed to advances in this fast moving field.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
EHA 2019 | Real-world data from the first French cohort of patients treated with CAR T-cell therapy
Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, reports on the first French patients treated with CAR T.
EHA 2019 | AUGMENT study: Post-hoc analysis in MZL
Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, shares a post-hoc analysis from AUGMENT study in marginal zone lymphoma (MZL).
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox